NEW YORK (GenomeWeb News) – UK non-profit the Wellcome Trust will use Affymetrix’s genotyping technologies for the second phase of its Case Control Consortium project, Affy said yesterday.
The WTCCC is a group of UK researchers who began in 2005 studying thousands of genotyped human samples for genes associated with coronary heart disease, hypertension, types 1 and 2 diabetes, bipolar disorder, Crohn's disease, rheumatoid arthritis, and tuberculosis.
For this second phase of the program, researchers will analyze genetic information from 30,000 individuals using Affy’s Genome-Wide Human SNP Array 6.0, as well as 6,000 common controls, the company said.
The consortium is also using Illumina arrays for the project.
In this leg of the study, the 14 research groups involved in the WTCCC aim to analyze the genetic information of 60,000 individuals for genetic links to 14 diseases and drug responses. These include schizophrenia, ulcerative colitis, psychosis, bacteriosis, pre-eclampsia and statin response, and a genome-wide association study of learning difficulties.
In the first study, the WTCCC detected 24 genetic associations across bipolar disorder, Crohn's disease, hypertension, rheumatoid arthritis, and type 1 and type 2 diabetes.
The company said the genotyping services are being conducted through a partnership with the Affymetrix Services Lab.
Financial terms of the agreement were not released.